Porton Advanced | ATMP CDMO/CRO

End-to-end ATMP CDMO/CRO that provides innovative offerings at each stage for biopharmaceutical products.

Founded 2018

Cranbury, United States 46 employees Series B Total: $480.00M Biotechnology, Health and Wellness +2

Porton Advanced is a Cell and Gene Therapy (CGT) CDMO\/CRO that offers a comprehensive range of services for biopharmaceutical products. Established in 2018 and headquartered in the United States, the company focuses on end-to-end research grade, process development, analytical development, GMP manufacturing, and testing services for AAV, Lentivirus, mRNA, and plasmid-based therapies. The company's dedicated teams have built robust platform-based USP\/DSP and GMP manufacturing capabilities and proprietary technologies to support client success. Porton Advanced offers a wide array of services including gene and cell engineering discovery research, technology licensing, process development, analytical development, testing, drug substances (DS), drug products (DP), and cGMP manufacturing across various therapeutic platforms. In August 2022, the company secured an impressive $80.00M Series B investment from a consortium of investors including Fosun Capital, China Merchants Group, HM Capital, Gortune Investment, China Merchants Securities, Ruilin Investment, SDICTK, CS Capital, Porton Pharma Solutions, and China Merchants Venture Capital. This investment underlines the confidence of key players in the industry in Porton Advanced's innovative offerings and capabilities. With a focus on Biotechnology, Manufacturing, and Pharmaceutical industries, Porton Advanced is well-positioned to continue its growth trajectory and make significant contributions to the cell and gene therapy landscape. For venture capital looking to invest in cutting-edge biopharmaceutical technologies, Porton Advanced presents a compelling opportunity to be at the forefront of innovation.

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	$80.00M	10	Fosun Capital, China Merchants Group +8	21 Aug 2022
Series A	CNY400.00M	-		16 Apr 2021

Funding Stage

Amount

Investors

Lead Investors

Date

Series B

$80.00M

Fosun Capital, China Merchants Group +8

21 Aug 2022

Series A

CNY400.00M

16 Apr 2021

FAQ About Porton Advanced | ATMP CDMO/CRO

End-to-end ATMP CDMO/CRO that provides innovative offerings at each stage for biopharmaceutical products.

Porton Advanced | ATMP CDMO/CRO was founded in 2018.

Porton Advanced | ATMP CDMO/CRO is headquartered in Cranbury, United States.

Porton Advanced | ATMP CDMO/CRO operates in Biotechnology, Health and Wellness, Manufacturing and Pharmaceutical. Its work centres on Cell and Gene Therapy, CDMO, CRO and Biopharmaceutical.

Porton Advanced | ATMP CDMO/CRO has approximately 46 employees.

Porton Advanced | ATMP CDMO/CRO has completed 2 funding rounds, raising a total of $480.00M. The latest funding stage is Series B.

Top alternatives and competitors to Porton Advanced | ATMP CDMO/CRO include RoslinCT, WuXi Advanced Therapies, Andelyn Biosciences, IDT Biologika, VintaBio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Porton Advanced | ATMP CDMO/CRO and RoslinCT are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Porton Advanced | ATMP CDMO/CRO

General Information

Discover More

About Porton Advanced | ATMP CDMO/CRO

Funding Rounds & Investors (2)

Porton Advanced | ATMP CDMO/CRO Alternatives & Competitors

FAQ About Porton Advanced | ATMP CDMO/CRO